Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SHEZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5,028,851 | $7,504,214 | $7,292,642 | $13,980,618 |
| - Cash | $1,689,041 | $1,851,642 | $2,138,779 | $2,944,257 |
| + Debt | $2,977,762 | $3,781,179 | $6,463,903 | $5,654,191 |
| Enterprise Value | $6,317,572 | $9,433,751 | $11,617,765 | $16,690,552 |
| Revenue | $5,280,713 | $5,445,572 | $7,159,411 | $6,365,177 |
| % Growth | -3% | -23.9% | 12.5% | – |
| Gross Profit | $1,756,155 | $944,923 | $2,334,401 | $2,033,039 |
| % Margin | 33.3% | 17.4% | 32.6% | 31.9% |
| EBITDA | $1,198,465 | -$320,447 | $1,383,292 | $731,274 |
| % Margin | 22.7% | -5.9% | 19.3% | 11.5% |
| Net Income | $646,742 | -$783,258 | $727,426 | $240,788 |
| % Margin | 12.2% | -14.4% | 10.2% | 3.8% |
| EPS Diluted | 0.44 | -0.53 | 0.5 | 0.16 |
| % Growth | 183% | -206% | 212.5% | – |
| Operating Cash Flow | $2,194,132 | $398,216 | -$756,613 | -$6,629 |
| Capital Expenditures | -$202,769 | -$444,878 | -$222,421 | -$193,861 |
| Free Cash Flow | $1,991,363 | -$46,662 | -$979,034 | -$200,490 |